Inflammatory bowel diseases are associated with a variety of extra-intestinal manifestations. The most frequent of these is joint involvement, which affects 16–33 % of IBD patients. Our aim was to evaluate the ultrasound prevalence of sub-clinical joint and entheseal involvement in patients with IBD without musculoskeletal symptoms, and to correlate the US findings with clinical and laboratory variables.
Methods
We recorded the clinical and laboratory data of 76 patients with IBD, 20 patients with spondyloarthritis (SpA) and 45 healthy controls at three rheumatology centers. All of the IBD patients and healthy controls were clinically examined by a rheumatologist in order to confirm the absence of musculoskeletal symptoms, and all of the subjects underwent grey-scale (GS) and power Doppler (PD) US examinations of the second and third metacarpophalangeal joints, knees and lower limbs in order to detect joint or entheseal abnormalities.
Results
A total of 1410 entheseal sites and 1410 joints were evaluated by US. Of the 76 patients with IBD, 64 (84.1 %) had at least one GS entheseal abnormality, and 11 (13.9 %) had more than one PD-positive entheseal site; 32 (42.1 %) showed sub-clinical joint involvement.
There was a significant difference between the IBD patients and healthy controls in terms of global entheseal, PD-positive entheseal, and joint involvement (p < 0.0001), but no difference between the IBD and SpA patients. Anti-neutrophil cytoplasmic antibodies predicted entheseal involvement in patients with IBD (OR 6.031; p = 0.015).
Conclusions
The prevalence of sub-clinical joint and entheseal involvement was higher in IBD patients than healthy controls, but there was no difference between the IBD and SpA patients.
The authors declare that they have no competing interests.
Authors’ contributions
JR participated in the design of the study, data collection and performed the statistical analysis. CD carried out evaluation of the subjects and performed statistical analysis. AB, PSP, FP and AD participated in subject evaluation and data collection. MG participated in study design and data acquisition. All authors have been involved in drafting the manuscript or revising it critically for important intellectual content and have given final approval of the version to be published.
Abkürzungen
IBD
inflammatory bowel disease
CDAI
Crohn’s Disease Activity Index
SpA
spondyloarthritis
HC
healthy controls
CD
chron disease
UC
ulcerative colitis
PD
power Doppler
GS
grey scale
CRP
c-reactive protein
ESR
erythrocyte sedimentation rate
pANCA
anti-neutrophil cytoplasmic antibodies
ASCA
anti-Saccharomyces cerevisiae antibodies
AZA
azathioprine
5 ASA
5 asa compounds
Background
Nearly four million people worldwide are affected by inflammatory bowel diseases (IBD) [1], which are associated with a variety of extra-intestinal manifestations [2]. The most frequent of these is joint involvement, which affects 16–33 % of IBD patients, [2‐4] whereas 5–10 % are affected by enthesitis [5].
Musculoskeletal involvement is a major concern in IBD patients as it increases disability and worsens their quality of life. However, its prevalence is frequently underestimated because of the transient manifestation of some oligoarticular patterns or the use of chronic corticosteroid treatment [6], because enthesitis is mistakenly attributed to overuse, or because the recognition of joint and tendon involvement may be delayed by the fact that gastroenterologists may not specifically enquire about musculoskeletal symptoms in everyday clinical practice [7]. It is therefore necessary to adopt a multidisciplinary approach in order to ensure that it is detected and appropriately treated early enough to avoid poor outcomes.
Anzeige
Ultrasonography (US) is a valid tool of detecting joint and tendon involvement early in patients with various rheumatic conditions. It is more sensitive than a clinical examination in revealing synovitis [8‐13] and enthesitis [14‐18], and can detect pathological changes even in the absence of symptoms [19‐24].
The aims of this US study were to evaluate the prevalence of sub-clinical joint and entheseal involvement in patients with IBD, and correlate the findings with clinical and laboratory data.
Methods
Patients with a definite diagnosis of IBD made by an experienced gastroenterologist on the basis of clinical, histological, endoscopic, radiological and laboratory data, and without any musculoskeletal symptoms were recruited by the outpatient gastroenterology and rheumatology departments of the study centers. There were two control groups: one consisting of patients with spondyloarthritis (SpA) diagnosed on the basis of the Assessment of SpondyloArthritis international Society (ASAS) criteria [25‐27], and the other of age- and gender-matched healthy subjects.
All of the subjects underwent a rheumatological examination by an expert rheumatologist blinded to their clinical condition in order to assess musculoskeletal involvement, and all of the patients underwent an US examination of the second and third metacarpophalangeal (MCP) joints, knees and lower limbs. The clinical and US assessments were made separately one immediately after the other by two investigators who were unaware of the other’s findings.
Anzeige
The exclusion criteria were an age of <18 years, a body mass index (BMI) of >30, a history of any inflammatory, microcrystalline, degenerative or infectious musculoskeletal disease, lower limb peripheral neuropathy, a history of severe trauma, knee or ankle surgery, or corticosteroid injections in the examined structures. IBD patients with signs of synovitis or enthesitis at clinical examination were also excluded.
All subjects gave informed consent to participate in the study, which was conducted in accordance with the Declaration of Helsinki and approved by Comitato Etico dell’Azienda Sanitaria Unica Regionale di Ancona.
Clinical assessment
Disease activity in all of the IBD patients was evaluated by a gastroenterologist using the Crohn’s Disease Activity Index (CDAI) [28] and a modified version of the ulcerative colitis (UC) Mayo Index [29] without the endoscopic assessment. CD remission was defined as a CDAI score of <150 score and UC remission as ≤3 bowel movements without blood.
Data concerning disease duration, the number of flares, anti-Saccharomyces cerevisiae (ASCA) and perinuclear anti-neutrophil antibodies (pANCA) profiles, HLA-B 27 status, the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) levels, current medications and BMI were recorded upon study entry.
The rheumatological evaluation was made by an experienced rheumatologist using a standard protocol that included confirmation of the absence of musculoskeletal symptoms or a history of any musculoskeletal disease, or any disorder that may have had musculoskeletal effects; the recording of all drugs received in the 12 weeks preceding study inclusion; a history of bone fracture and joint surgery; and a physical examination assessing the swelling and tenderness of the second and third MCP joints, knees, ankles, and first metatarsophalangeal (MTP) joint and entheses.
US assessment
The US examinations were performed by one investigator in each study centre who was blinded to the subject status and to whom the subjects were asked not to mention their condition. Before beginning the study, the investigators had reached a consensus concerning on the scanning technique and the findings to search for. The machines used were a MyLab Twice (Esaote S.p.A., Genova, Italy), a MyLab 70XVG (Esaote S.p.A., Genova, Italy.) and a GE LOGIQ P5 (General Electric Company, Little Chalfont, United Kingdom), all of which were equipped with a 6–18 MHz broadband linear transducer. Each anatomical area (the second and third MCP joints, knees, ankles, and first MTP joints) was bilaterally scanned first in grey scale (GS) in order to detect any morphostructural changes, and subsequently with power Doppler (PD with a pulse repetition frequency of 500–1000 Hz and a Doppler frequency of 6–9.1 MHz) in order to detect abnormal blood flow. The examination also investigated the quadriceps, distal and proximal patellar, Achilles, and proximal plantar aponeurosis entheseal insertion.
During the multiplanar exploration of the MCP joints, the subject sat with his or her hands on the examination table and fingers extended but relaxed. The knee was scanned with the subject in supine decubitus with the knee in a neutral position, and the tibiotalar joint with the subject in supine decubitus, the knee flexed 45°, and the foot resting over its plantar aspect with slight plantar flexion. The MTP joints were scanned with the patient in supine decubitus, the knee flexed 45°, the foot resting over its plantar aspect, and the toes extended and relaxed [30]. During the examinations of the superior (quadriceps enthesis) and inferior pole of the patella (patellar enthesis), and the patellar enthesis at the anterior tibial tuberosity, the subject was supine with extended lower limbs; the Achilles tendon and proximal plantar aponeurosis were examined with the patient lying prone with feet hanging over the edge of the examination table at 90° of flexion [30].
All of the US findings indicative of enthesopathy were based on the OMERACT definition [31]. A PD abnormality was considered positive if at least a single vessel was present at < 2 mm of cortical bone and not at tendon body or bursal level.
Anzeige
The supra-patellar pouch, MCP, knee, ankle and MTP joints were assessed for synovial fluid and synovial hypertrophy. Synovial fluid was considered documented in the presence of anechoic or hypoechoic joint cavity widening displacable/compressible by ultrasound probe, and synovial proliferation in the presence of abnormal hypo- or hyperechoic not compressible material inside the joint cavity [31]. All sites were scanned in longitudinal and transversal views and the alterations considered present if seen in both views. Both the GS and PD findings were qualitatively assessed (i.e. present/absent).
Statistical analysis
The continuous variables are expressed as mean values ± standard deviation (SD) or median values and interquartile range (IQR) as appropriate, and the categorical variables as percentages. The associations between joint/PDUS/entheseal abnormalities and clinical variables were evaluated using the Mann–Whitney test in the case of continuous variables and the χ2 test in the case of categorical variables. A binary logistic regression model containing all of the variable that were significant in the univariate analysis was used to establish the variables predicting joint/PDUS/entheseal abnormalities.
The data were analyzed using SPSS software, version 20 (Chicago, Illinois, 2011), and a value of p < 0.05 was considered statistically significant.
Results
One hundred and forty one subjects were recruited: 76 with IBD (43 with CD, and 33 with UC), 20 patients with established SpA (12 Ankylosing spondylitis, 8 non-radiographic axial SpA), and 45 healthy controls. Table 1 shows the characteristics of the IBD patients.
Table 1
Clinical and laboratory characteristics of IBD patients
Crohn’s disease/Ulcerative colitis
43/33 patients
Age
39.93 ± 14.02 years
BMI
23.36 ± 4.13 kg/m2
Disease duration
7.91 ± 6.18 years
Active/inactive bowel disease
51.3 %/48.7 %
Disease flares
2.53 ± 1.97
ASCA positive
25 % (CD)
pANCA positive
18.4 % (17 % UC + 1.4 % CD)
HLA B 27 positive
2.6 %
CRP
0.69 ± 0.96 mg/dL
ESR
14.52 ± 11.48 mm/h
Medications
- Corticosteroids
19.7 %
- 5 ASA
42.1 %
- Anti-TNFα
32.9 %
- Azathioprine
28.9 %
- Cyclosporine
1.3 %
Anzeige
US was used to evaluate a total of 1410 entheseal sites and 1410 joints. Of the 76 patients with IBD, 84.1 % had at least one entheseal abnormality (from a total of 60 per patient), 50 % had at least three, 40.8 % more than five, and 17.1 % had more than 10 abnormalities (GS and PD); 24 (31.6 %) had at least one PD-detected abnormality, and 11 were PD-positive at more than one entheseal site. The patellar tendon was the most affected entheseal site (a total of 218 detected abnormalities out of 1824), followed by the quadriceps tendon. Ultrasound normal and abnormal findings at the four entheseal sites are exhibited in Fig. 1. Thirty-two of the 76 IBD patients showed sub-clinical joint involvement. Excluding the first MTP (because of the frequency of paraphysiological abnormalities), the knee was the most affected joint (24 irregularities out of 456), followed by the ankle with eight.
No significant difference was found in the detection rates of abnormal findings in each institution.
Table 2 shows the prevalence of joint and entheseal involvement. There was a significant difference between the IBD patients and healthy controls (p < 0.0001), but no difference between the IBD and SpA patients, and no apparent difference between the patients with CD and UC (Table 3).
Table 2
Ultrasound findings by disease status
IBD
SpA
HC
All joints
21 (48.8 %)
8 (40 %)
4 (8.9 %)*
MCP
3 (5.2 %)
1 (1.31 %)
0 (0 %)*
Knee
12 (15.8 %)
6 (30 %)
2 (4.4 %)*
Ankle
7 (11.3 %)
7 (35 %)**
0 (0 %)*
1st MTP
17 (22.4 %)
8 (40 %)
2 (4.4 %)*
All entheseal sites
63 (82.9 %)
20 (100 %)
13 (28.9 %)*
Quadriceps tendon
31 (40.8 %)
11 (55 %)
2 (4.4 %)*
Patellar tendon
51 (67.1 %)
19 (95 %)**
2 (4.4 %)*
Achilles tendon
33 (43.4 %)
13 (65 %)
5 (11.1 %)*
Plantar fascia
19 (25 %)
12 (60 %)**
2 (4.4 %)*
Entheseal power Doppler
25 (32.9 %)
11 (55 %)
0 (0 %)*
Number of subjects with the alteration and their relative prevalence (%)
IBD inflammatory bowel disease, SpA spondyloarthritis, HC healthy controls
*IBD vs HC p < 0.0001; **IBD vs SpA p < 0.01
Table 3
Ultrasound findings in CD and UC
CD
UC
All joints
11 (25.5 %)
10 (30.3 %)
MCP
3 (6.9 %)
0 (0 %)
Knee
4 (9.3 %)
8 (24.2 %)
Ankle
4 (9.3 %)
3 (9.1 %)
1st MTP
11 (25.5 %)
6 (18.2 %)
All entheseal sites
37 (86 %)
26 (78.8 %)
Quadriceps tendon
16 (37.2 %)
15 (45.5 %)
Patellar tendon
31 (72.1 %)
20 (60.6 %)
Achilles tendon
16 (37.2 %)
17 (51.5 %)
Plantar fascia
8 (18.6 %)
11 (33.3 %)
Entheseal power Doppler
15 (34.9 %)
10 (30.3 %)
Number of subjects with the alteration and their relative prevalence (%)
No significative difference was found between groups
CD Chron disease, UC Ulcerative colitis
There was no association between joint involvement and the clinical or laboratory data of the IBD patients but, interestingly, global US entheseal abnormalities were associated with the presence of pANCA (p = 0.011) and current treatment with azathioprine (p = 0.014). pANCA also predicted entheseal involvement in the IBD patients (OR 6.031; p = 0.015). PD-detected entheseal abnormalities correlated with the number of IBD flares (p = 0.009), CRP (p = 0.044) and current treatment with azathioprine (p = 0.005).
Anzeige
No other associations were found between the clinical and laboratory data and US-detected entheseal involvement (Tables 4, 5 and 6).
Table 4
Clinical and laboratory data by PD- and GS-detected entheseal abnormalities
PD-detected entheseal abnormalities
GS-detected entheseal abnormalities
GS + PD detected entheseal abnormalities
present
absent
p
present
absent
p
present
absent
p
Agea
52 (23.5-58.3)
38 (29–45)
0.707
40 (28–56)
33.5 (24.5-38.5)
0.155
40 (28–56)
33.5 (24.5-38.5)
0.102
BMIa
22.59 (19.9-24.6)
23.24 (19.9-25.9)
0.608
23.4 (20.9-26.4)
21.9 (19.7-24.4)
0.297
23.24 (20.9-26.4)
21.87 (19.7-24.4)
0.297
Disease durationa
6 (2.3-9.5)
7 (4.5-12)
0.695
7 (4–12)
6.5 (4.5-10)
0.724
7 (4–12)
6.5 (4.5-10)
0.972
Disease flarea
2.50 (2–3.75)
3 (2–5)
0.009*
4 (2–5)
2 (1.75-53)
0.204
4 (2–5)
2 (1.75-3)
0.295
Active diseaseb
21
79
0.883
0
100
0.53
9.1
91.9
0.721
ESRa
8.5 (5.3-9.8)
10 (6–17.5)
0.224
8 (5–11)
14.5 (10–29)
0.116
8 (5–11)
14.5 (10–29)
0.196
CRPa
0.35 (0.19-075)
0.19 (0.09-0.8)
0.044*
0.19 (0.1-0.61)
0.4 (0.1-1.3)
0.116
0.19 (0.1-0.6)
0.4 (0.1-1.35)
0.796
ASCAb
15.8
84.2
0.127
78.9
21.1
0.991
30
70
0.822
pANCAb
21.4
78.6
0.476
57.1
42.9
0.022*
16
84
0.011*
Steroidsb
14.3
85.7
0.271
14.2
85.8
0.835
9.4
90.6
0.909
Anti-TNFαb
40
60
0.356
92
8
0.14
37.5
62.5
0.05
AZAb
9
91
0.005*
68.1
31.9
0.030*
23.4
76.6
0.014*
5 ASAb
40
60
0.745
41.2
58.8
0.745
39.1
60.0
0.727
amedian values (interquartile ranges), Mann–Whitney U test; bpercentages (%), χ2 test
GS grey scale, PD power Doppler, pANCA: anti-neutrophil cytoplasmic antibodies, CI confidence interval
Table 6
Multivariate logistic regression models predicting GS- and PD-detected entheseal abnormalities
GS-detected entheseal abnormalities
PD-detected entheseal abnormalities
GS + PD-detected entheseal abnormalities
Exp (B)
95 % IC
p
Exp (B)
95 % CI
p
Exp (B)
95 % CI
p
Lower
Upper
Lower
Upper
Lower
Upper
Azathioprine
2.915
0.775
10.971
0.114
4.210
0.797
22.252
0.091
3.831
0.934
15.716
0.062
pANCA
4.755
1.195
18.915
0.027
-
6.031
1.412
25.757
0.015
Disease flares
-
0.704
0.486
1.019
0.063
-
CRP
-
1.128
0.641
1.985
0.677
-
GS grey scale, PD power Doppler, pANCA anti-neutrophil cytoplasmic antibodies, CI confidence interval, CRP C-reactive protein
Discussion
This is the first multicenter study to explore joint and entheseal involvement in IBD patients with no signs or symptoms of musculoskeletal disease and, to the best of our knowledge, the first time that this has been compared in IBD and SpA patients.
Our findings indicate that the prevalence of sub-clinical entheseal and joint involvement is in high with patients with IBD. The prevalence of sub-clinical entheseal involvement is in line with the 92.6 % reported by Bandinelli et al. [23], although they found a higher prevalence of PD-detected involvement (32.9 % vs 16 %). Enthesitis is often the first sign of SpA in young adults [32], but only a small percentage of cases are discovered by means of a clinical examination: for example, in a cross sectional study of 130 Brazilian IBD patients, a clinical assessment identified enthesitis in only (5,4 %) [2], and Balint found the sensitivity of a clinical examination was low in patients with SpA [14].
As found in previous studies [23], the most affected entheseal site in our patients was the patellar tendon, followed by the Achilles tendon, which is often indicated as being the most affected in patients with SpA [33, 34]. On the contrary, the prevalence of frequently described plantar fascia abnormalities was lowest, possibly because the thicker layer of subcutaneous tissue and skin in this anatomical region reduces the sensitivity of US.
Arthritis is a common finding, and has been reported in 17–39 % of patients with IBD [6]. We found that the prevalence of joint alterations was as high as 48.8 %, although one magnetic resonance imaging (MRI) study of 11 IBD patients with painful hand joints without clinical synovitis and 11 without painful joints found no signs of synovitis in the latter [35]. However, the number of patients was small and the study only considered hand joints.
Some studies have confirmed the relationship between sub-clinical gut and joint inflammation [32, 36‐38]. The GIANT cohort study found microscopic gut inflammation in 46 % of the SpA patients (the prevalence was higher in those with axial SpA than those with peripheral SpA), and one recent MRI study [39] found that chronic gut inflammation was associated with sacroiliac joint bone marrow edema.
In our study we found that azathioprine was associated with increased entheseal involvement in IBD patients. It has been shown a direct relationship between the extent of colonic disease and the presence of extraintestinal manifestations [4]. Patients under treatment with azathioprine could have higher bowel disease activity and could also have more extraintestinal features including entheseal involvement. It is also known that azathioprine is not an effective pharmacological treatment in SpA and therefore these patients may have more entheseal manifestations.
We also found an association between pANCA and entheseal involvement in IBD patients. It has been suggested that atypical pANCA cross-react with luminal bacteria and the environmental antigens driving the inflammatory process [40], and they have also been found to be associated with isolated colonic disease [41, 42] and 4-fold risk of undergoing azathioprine treatment [41]. Remarkably, colectomy seems to protect IBD patients against the development of peripheral arthritis [43].
Interestingly, we did not find any difference in US-revealed entheseal involvement between our patients with IBD and those with SpA. A multidisciplinary approach is useful when following up IBD patients because the transient nature of the oligoarticular pattern of arthritis, the use of corticosteroids to manage IBD flares [6] or the attribution enthesitis to overuse, may lead clinicians to underestimate the prevalence of arthritic involvement. Moreover, gastroenterologists may not specifically ask about musculoskeletal symptoms in clinical daily practice, thus leading to the delayed recognition of joint and entheseal involvement [7].
This study has some limitations. First of all, as US is sensitive to small alterations, the fact that the data were recorded dichotomously may have led to an overestimate of particularly joint involvement. Secondly, the prevalence of pANCA was lower in our patients than that reported in the literature [40‐42], and this may have affected our findings concerning their predictive value for entheseal involvement. Thirdly, the small study cohort did not allow us to measure the real dimension of the prevalence of entheseal involvement in IBD patients. Fourthly, the study is not powered enough to detect differences between IBD and SpA groups. We estimate a sample size of 49 for entheseal involvement and 500 for articular involvement considering a type I error of 0.05 and power of 80 %.
Conclusion
We found a high prevalence of sub-clinical joint inflammation in IBD patients without any musculoskeletal signs or symptoms, and an association between pANCA and entheseal involvement, but further studies are necessary to confirm the latter finding. However, the question as to how such patients should be treated and followed up remains open as prospective studies are necessary in order to clarify the prognostic value of our findings.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JR participated in the design of the study, data collection and performed the statistical analysis. CD carried out evaluation of the subjects and performed statistical analysis. AB, PSP, FP and AD participated in subject evaluation and data collection. MG participated in study design and data acquisition. All authors have been involved in drafting the manuscript or revising it critically for important intellectual content and have given final approval of the version to be published.
Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.
Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.
Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.
Update Orthopädie und Unfallchirurgie
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
